LCM
PRVB

Laurion Capital Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Laurion Capital Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-68,340
Closed -$1.02M – 1174
2019
Q4 		$1.02M Buy
68,340
+54,940
+410% +$490K 0.01% 567
2019
Q3 		$91K Buy
+13,400
New +$136K ﹤0.01% 951

Other funds holding PRVB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Laurion Capital Management's PRVB Position: Q1 2020 in Review

Laurion Capital Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2020, closing a stake of 68,340 shares — an estimated $1.02M sold.

Laurion Capital Management first reported a position in PRVB in Q3 2019 and held it in 2 quarters. The position peaked at $1.02M in Q4 2019. 63 funds tracked by Wall St. Rank hold PRVB as of Q1 2020.

  • Laurion Capital Management reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Laurion Capital Management sold 68,340 Provention Bio, Inc. Common Stock shares in Q1 2020, an estimated $1.02M.
  • Laurion Capital Management first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Laurion Capital Management's Provention Bio, Inc. Common Stock position peaked at $1.02M in Q4 2019.
  • 63 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2020.

Based on Laurion Capital Management's 13F filing for Q1 2020, filed 14 May 2020.